Trial Profile
Phase II trial of perioperative chemotherapy for esophageal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Adenosquamous carcinoma; Basal cell cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PIECE Trial
- 07 Jun 2022 Status changed to completed, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Primary endpoint has been met (three-year relapse free survival) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology